Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-10-02
2011-11-29
Tsang, Cecilia J (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S001210, C530S331000, C977S773000
Reexamination Certificate
active
08067380
ABSTRACT:
A delivery system is provided. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene glycol derivative.
REFERENCES:
patent: 5080904 (1992-01-01), Iga et al.
patent: 5695751 (1997-12-01), Friedman et al.
patent: 6627732 (2003-09-01), Sakon et al.
patent: 6653331 (2003-11-01), Zhao et al.
patent: 7446096 (2008-11-01), Wang et al.
patent: 7700564 (2010-04-01), Wang et al.
patent: 7704956 (2010-04-01), Liang et al.
patent: 2003/0109555 (2003-06-01), Zhao et al.
patent: 2009/0123531 (2009-05-01), Wang et al.
patent: 1 072 608 (2001-01-01), None
patent: 2 627 385 (1989-08-01), None
patent: 63-2922 (1988-01-01), None
patent: WO-99/54346 (1999-10-01), None
patent: WO-00/28977 (2000-05-01), None
Chinese Office Action for Copending Application No. 200610005869.0, dated Dec. 15, 2010.
Banks et al., Life Sciences, vol. 59, No. 23, 1996, pp. 1923-1943.
Zlokovic et al., Biochemical and Biophysical Research Communications, vol. 201, No. 1, May 30, 1994, pp. 402-408.
Kannan et al., The Journal of Biological Chemistry, vol. 271, No. 16, Apr. 19, 1996, pp. 9754-9758.
Kannan et al., Journal of Neurochemistry, vol. 73, No. 1, 1999, pp. 390-399.
Kannan et al., Elsevier Science B.V., 2000, pp. 374-382.
Zlokovic, Pharmaceutical Research, vol. 12, No. 10, 1995, pp. 1395-1406.
“Liposome carrier for liver disease treatment—contains N-higher acyl glutathione as base material”, Derwent, XP002322756, abstract (Jan. 7, 1988).
Kiwada et al., Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, Tokyo, JP., vol. 35, No. 7, pp. 2935-2942, XP002276804 (Jul. 7, 1987).
Suntres et al., Journal of Pharmacy and Pharmacology, London, GB, vol. 46, No. 1, pp. 23-28, XP001105800 (Jan. 1, 1994).
Jurima-Romet et al., Journal of Pharmacy and Pharmacology, London, GB, vol. 43, No. 1, pp. 6-10, XP001105806 (1991).
Sugiyama et al., Journal of Controlled Release, Elsevier, Amsterdam, NL, vol. 62, No. 1-2, pp. 179-186, XP004363015 (Nov. 1, 1999).
Kabanov, et al., 1982, Institute of Physical Chemistry, Academy of Sciences USSR, Moscow, pp. 771-775.
Office Action, dated Nov. 30, 2010, for Japanese Application No, 2005-374896.
Jian Chi-Heng
Li Shyh-Dar
Lin Yi-Fong
Liu Shin-Jr
Wang Ae-June
Birch & Stewart Kolasch & Birch, LLP
Gudibande Satyanarayana
Industrial Technology Research Institute
Tsang Cecilia J
LandOfFree
Glutathione-based delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glutathione-based delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glutathione-based delivery system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4288391